Skip to content
Menu

Stifel Maintains Buy on SpyGlass Pharma, Raises Price Target to $44

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.

Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.

Read at benzinga.com